Using Discrete Choice Experiment to elicit patient preferences for osteoporosis drug treatments: Where to from here?

Arthritis Research and Therapy

Volumn 16, Issue 2, 2014, Pages

  Laba, Tracey Lea ^a  

^a GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS ANALYSIS; DISCRETE CHOICE EXPERIMENT; EDITORIAL; EXPERIMENTAL STUDY; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; MEDICATION COMPLIANCE; OSTEOPOROSIS; PATIENT PREFERENCE; PATIENT SAFETY; PHARMACEUTICAL CARE; THERAPY EFFECT; DECISION MAKING; FEMALE; MALE;

BONE DENSITY CONSERVATION AGENT;

BONE DENSITY CONSERVATION AGENTS; CHOICE BEHAVIOR; FEMALE; HUMANS; MALE; OSTEOPOROSIS; PATIENT PREFERENCE;

EID: 84897449488     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4501     Document Type: Editorial

References (10)

1. Hiligsmann M, Dellaert BG, Dirksen CD, van der Weijden T, Goemaere S, Reginster JY, Watson V, Boonen A. Patients' preferences for osteoporosis drug treatment: a discrete-choice experiment. Arthritis Res Ther 2014, 16:R36. 10.1186/ar4465, 24479410.
2. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet 2011, 377:1276-1287. 10.1016/S0140-6736(10)62349-5, 3555696, 21450337.
3. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporosis Int 2006, 17:1726-1733.
4. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007, 22:465-475. 10.1359/jbmr.061113, 17144789.
5. Gold DT. Understanding patient compliance and persistence with osteoporosis therapy. Drugs Aging 2011, 28:249-255. 10.2165/11586880-000000000-00000, 21553400.
6. Bridges JF, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, Johnson FR, Mauskopf J. Conjoint analysis applications in health - a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health 2011, 14:403-413. 10.1016/j.jval.2010.11.013, 21669364.
7. Laba TL, Brien JA, Fransen M, Jan S. Patient preferences for adherence to treatment for osteoarthritis: the MEdication Decisions in Osteoarthritis Study (MEDOS). BMC Musculoskelet Disord 2013, 14:160. 10.1186/1471-2474-14-160, 3660275, 23647688.
8. Laba TL, Brien JA, Jan S. Understanding rational non-adherence to medications. A discrete choice experiment in a community sample in Australia. BMC Fam Pract 2012, 13:61. 10.1186/1471-2296-13-61, 3511288, 22715853.
9. Bridges JF, Dong L, Gallego G, Blauvelt BM, Joy SM, Pawlik TM. Prioritizing strategies for comprehensive liver cancer control in Asia: a conjoint analysis. BMC Health Serv Res 2012, 12:376. 10.1186/1472-6963-12-376, 3529196, 23110423.
10. Hiligsmann M, van Durme C, Geusens P, Dellaert BG, Dirksen CD, van der Weijden T, Reginster JY, Boonen A. Nominal group technique to select attributes for discrete choice experiments: an example for drug treatment choice in osteoporosis. Patient Prefer Adherence 2013, 7:133-139. 3572758, 23412964.